Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Vivax malaria used to be considered benign but is now recognised as an important cause of morbidity and mortality. Resistance to chloroquine (given to treat the parasite blood stage) is growing and ACT (artemisinin-based combination therapy) is becoming common treatment for vivax malaria. New drugs and better public health strategies can help elimination targets, anticipated for 2030.

My name is Ric Price, I’m a Professor of Tropical Medicine at the Nuffield Department of Medicine in Oxford.

There are 5 species of malaria that cause disease in humans, and Plasmodium vivax is probably the second most important after falciparum. P. vivax can cause an appreciable morbidity and mortality; it was once known as a benign malaria, but it’s certainly not benign. It can reoccur weeks to months after the initial infection and that causes anaemia and recurrent diseases, and young children and pregnant women are particularly vulnerable to the disease.

You have to treat both the blood stage of the parasite, that’s the one that causes the illness and the fever, and you also have to treat the stages that go to sleep in the liver, they’re called the dormant hypnozoites. We have to give a combination of two drugs; most of the world uses chloroquine and you add to that primaquine for the liver stages. But the tricky thing is that the parasite is now becoming resistant to chloroquine, and primaquine you have to treat for 14 days, and if they don’t take a complete treatment course then the parasite will come back and will reoccur or relapse. There’re new drugs coming: there’s an exciting drug called tafenoquine which can be given as a single dose instead of a 14 day regimen. But now we have to identify new diagnostics so that people can safely be given this drug, even in areas where there’s G6PD deficiency.

Drug resistant vivax was first reported in about 1991 in the island of Irian Jaya, and now it’s at very high levels: maybe 50-60% of people fail their treatment with chloroquine. On a recent review we found evidence of low grade resistance throughout most of the vivax endemic world, so chloroquine resistance is here and it’s probably getting worse and we need to do something about it. ACT (artemisinin combination therapy) is used for falciparum malaria and it’s also highly effective for vivax malaria. So several countries now are abandoning chloroquine and are using ACT for both falciparum and vivax malaria.

I think that the biggest progress we’ve made in the last 10 years is to appreciate that vivax is important. It was neglected and people didn’t think that it would cause disease. We now have clear evidence that the repeated infections are associated with significant morbidity and mortality. As the policy makers and the funders appreciate the burden, they’re paying more attention, so this disease was once neglected is now becoming increasingly important in the elimination agenda. The burden of vivax is difficult to gauge, but it’s probably in the order of 20-30 million cases a year, and we estimate that that costs health care communities and patients and their families about half a billion dollars a year.

Our research is specifically focused on changing policy and impacting on health. If we don’t achieve that with P. vivax, we’ll never achieve the elimination targets, which in Southeast Asia is anticipated to be in 2030, that’s only 12 years away. There’s no opportunity for complacency and if we want to achieve that, we have to eliminate the parasite. My translational research agenda aims to tackle the primary obstacles for vivax elimination, and we divide that into three themes: surveillance – which populations are at risk of the disease? Diagnostics – so new diagnostics of how can we diagnose vivax and also people with G6PD deficiency? And thirdly – how can we give better treatments which are more effective and impact upon the disease? All of those activities are focused around the management of the patient and the public health strategies to reduce the parasite, so that’s very translational.

Ric Price

The main focus of Professor Price translational research programme is to improve the diagnosis and management of Plasmodium vivax malaria. To achieve this, he is working with 15 malaria endemic countries across the Asia-Pacific region and Horn of Africa, to establish surveillance as well as better diagnostics and treatment.

More podcasts related to Malaria

Bob Taylor: Primaquine for vivax and falciparum malaria

Primaquine can be used both to treat vivax malaria and to prevent the transmission of falciparum malaria from human to mosquito. A shorter and age-based primaquine regimen would reduce the burden of vivax malaria. It would also allow primaquine to be used more widely to block the transmission of falciparum malaria.

Lisa White: Mathematical modelling for tropical diseases

Mathematical modelling, particularly when combined with economical modelling, allows researchers and policy makers to determine the most effective interventions to fight infectious diseases such as malaria. We can use those models to explore ‘what ifs’ scenarios, at country or province level, save more lives and limit costs.

Olivo Miotto: Genomics and global health

Genomics is the study of the complete DNA sequence, for example of a particular parasite, allowing us to analyse its evolution and the impact of human interventions. Alongside clinical date, we use genomics to identify mutations that are markers for drug resistance. Mapping out drug resistance then helps inform elimination programmes.

Frank Smithuis: Fighting malaria in Myanmar

Although malaria is decreasing in Myanmar, resistance to anti-malarials is on the rise in the region and the focus is now to treat people early, particularly in remote communities. MOCRU has set up a network of community health workers, trained and supplied with diagnostics, bednets and treatments, to help improve access to healthcare as well as produce the evidence to encourage policy changes.

Andrea Ruecker: Blocking malaria transmission

In the falciparum malaria parasite cycle, the gametocyte stages are responsible for the transmission from person to mosquito, then to other persons. A better understanding of how gametocytes respond to malaria treatments would help us block transmission and ultimately eliminate malaria.

Rob van der Pluijm: Tracking antimalarial resistance and treatment of malaria using Triple ACTs

Anti-malaria drug resistance is spreading throughout Southeast Asia and we need to find new treatments. Our researchers at MORU use a combination of artemisinin and two partner drugs instead of one. If confirmed safe and tolerable, triple artemisinin combination therapies might be a good option to treat multi-drug resistant malaria, as well as slow down the emergence and spread of anti-malarial resistance.

James Watson: Primaquine and vivax malaria

Primaquine is a drug used to eliminate vivax malaria from the liver and prevent relapses. However, it causes anaemia in patients with G6PD deficiency. A new, slightly longer regimen with increasing doses of primaquine could allow to safely treat all patients with vivax malaria.

Xin Hui Chan: Using big data to eliminate malaria

Malaria is the most important parasitic infection to still affect humans, and a safe use of antimalarial drugs is paramount. The current explosion of clinical data is causing a jungle of data; making sense of all this data will greatly help us in our fight to eliminate malaria.

Bob Snow: Malaria control in Africa

Quality data is vital to design better malaria control programmes. This project helps various African countries gather epidemiological evidence to better control malaria. Professor Bob Snow showed how sub-regional, evidence-based platforms can effectively change malaria treatment policies.

Lorenz von Seidlein: Malaria elimination in the Greater Mekong sub-region

Multidrug resistant P. falciparum malaria is now established in parts of Thailand, Laos and Cambodia, causing high treatment failure rates for artemisinin combination therapies, the main falciparum malaria medicines.

Translational Medicine

From Bench to Bedside

Ultimately, medical research must translate into improved treatments for patients. At the Nuffield Department of Medicine, our researchers collaborate to develop better health care, improved quality of life, and enhanced preventative measures for all patients. Our findings in the laboratory are translated into changes in clinical practice, from bench to bedside.